Development and Approval of Combination Products: A Regulatory Perspective

A step-by-step, integrated approach for successful, FDA-approved combination drug products Using a proven integrated approach to combination drug development, this book guides you step by step through all the preclinical, clinical, and manufacturing stages. Written from an FDA regulatory perspective, the book not only enables you to bring a successful combination drug product to market, it also sets forth the most efficient and effective path to FDA approval. The book begins with an introductory chapter presenting definitions and basic regulatory principles of combination products. Next, it reviews manufacturing and controls, preclinical testing models, pharmacology, clinical testing, regulatory submissions, FDA reviews, and approvals. Among the key topics examined are: * The pharmacology, safety pharmacology, and toxicology supporting human clinical trials of combination products * Approaches to clinical trial protocol design and execution * Chemical, physicochemical, and analytical aspects of manufacturing controls and validation that lead to stable components for combination products * Key sponsor/FDA meetings and negotiations essential for approval and commercialization Case studies involving such actual combination products as Mylotarg, Herceptin, and HercepTest help you better understand how to implement the author's practical guidelines. References at the end of each chapter enable you to find more information on any stage of the development, manufacturing and approval processes. This book is ideal for researchers, regulators, academics, project managers, and executives involved in the complex process of combination product development. Not only does itoffer a comprehensive guide to the technical aspects of the field, it also integrates all ofthese technical aspects into a unified, effective approach to help ensure a successful, approved product.Content: Chapter 1 Overview of Combination Products Development and Regulatory Review (pages 1–4): Evan B. SiegelChapter 2 Detailed Regulatory Approaches to Development, Review, and Approval (pages 5–75): James BarquestChapter 3 Nonclinical Recommendations for Successful Characterization and Development of Combination Drug Products (pages 77–111): Duane B. LakingsChapter 4 Clinical Pharmacology and Clinical Development of Combination Products (pages 113–170): Chaline BrownChapter 5 Regulatory Strategy Considerations for Chemistry, Manufacturing, and Controls: An Integrated Approach (pages 171–200): Patrick L. DeVillier